Daily Journal Staff Writer
Sea changes in medical technology are having an impact on the California deal market as deal makers at some pharmaceutical companies look increasingly past fellow drug companies for their next purchase. Instead, they're buying medical device and life science companies. Corporate lawyers say midsize pharmaceutical companies face two dilemmas right now that are changing their shopping habits: how much money to ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In